CELU
HEALTHCARECelularity Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving CELU Today?
No stock-specific AI insight has been generated for CELU yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.93
Fundamentals
Trading
CELU News
20 articles- NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of DirectorsYahoo Finance·May 6, 2026
- Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic TransformationYahoo Finance·May 1, 2026
- NEXGEL Appoints Ian Blackman as Chief Financial OfficerYahoo Finance·Apr 27, 2026
- NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease SegmentYahoo Finance·Apr 21, 2026
- Celularity Announces Closing of Transaction with NexGelYahoo Finance·Apr 21, 2026
- NEXGEL, Inc. Q4 2025 Earnings Call SummaryMoby·Apr 21, 2026
- Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingYahoo Finance·Apr 17, 2026
- NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity TransactionYahoo Finance·Apr 15, 2026
- NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity TransactionYahoo Finance·Apr 8, 2026
- NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with CelularityYahoo Finance·Mar 31, 2026
- NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial ProductsYahoo Finance·Mar 12, 2026
- Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product OpportunitiesYahoo Finance·Mar 12, 2026
- Poolbeg Pharma adds CAR-T therapy expert to scientific advisory boardProactive Investors·Mar 12, 2026
- NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial ProductsYahoo Finance·Mar 10, 2026
- Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused StrategyYahoo Finance·Mar 10, 2026
- Celularity Receives $12.2 Million from Sale of New Jersey Net Operating LossesYahoo Finance·Feb 10, 2026
- Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage DeterminationsYahoo Finance·Dec 26, 2025
- Celularity Announces Closing of Financing TransactionsYahoo Finance·Dec 22, 2025
- Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic VisionYahoo Finance·Dec 18, 2025
- Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye CareYahoo Finance·Oct 30, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.93
Fundamentals
Trading
About Celularity Inc - Class A
Celularity Inc. is an innovative biotechnology company dedicated to pioneering regenerative medicine through its proprietary cellular products derived from the placenta. The firm boasts a robust pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, targeted at improving treatment efficacy and minimizing complications for cancer and other serious diseases. Supported by a seasoned leadership team and strategic collaborations, Celularity is strategically positioned to meet substantial unmet medical needs, thereby establishing itself as a pivotal entity in the dynamic landscape of advanced therapeutics.